Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion
Abstract We investigated the efficacy of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in branch retinal vein occlusion (BRVO). Databases, including PubMed, EMBASE, and the Cochrane Library, were searched on November 11, 2022. Studies comparing the pro-re-nata (PRN)...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-07-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-39303-2 |
| _version_ | 1797769513136029696 |
|---|---|
| author | Yoo-Ri Chung Tae Kyoung Woo Ha Ryung Park Kihwang Lee |
| author_facet | Yoo-Ri Chung Tae Kyoung Woo Ha Ryung Park Kihwang Lee |
| author_sort | Yoo-Ri Chung |
| collection | DOAJ |
| description | Abstract We investigated the efficacy of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in branch retinal vein occlusion (BRVO). Databases, including PubMed, EMBASE, and the Cochrane Library, were searched on November 11, 2022. Studies comparing the pro-re-nata (PRN) regimen after the first treatment (PRN group) to three consecutive monthly injection regimens followed by the PRN regimen (3 + PRN group) were investigated. The primary outcomes were the change in best-corrected visual acuity (BCVA) and the change in central retinal thickness (CRT), with the secondary outcome being the injection frequency. Among 195 reports on anti-VEGF treatment, six comparative studies were included in this meta-analysis. The two groups had no statistically significant differences in terms of BCVA or CRT. However, the total number of injections during follow-up was significantly lower in the PRN group than in the 3 + PRN group (95% CI − 2.09 to − 0.83). The as-needed injection regimen is as effective as 3-monthly loading in terms of anatomical and functional improvement for BRVO, along with a lower treatment burden for patients and physicians. |
| first_indexed | 2024-03-12T21:10:09Z |
| format | Article |
| id | doaj.art-911b55ce6fba4ea697ba5df808bf8230 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-12T21:10:09Z |
| publishDate | 2023-07-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-911b55ce6fba4ea697ba5df808bf82302023-07-30T11:14:19ZengNature PortfolioScientific Reports2045-23222023-07-011311710.1038/s41598-023-39303-2Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusionYoo-Ri Chung0Tae Kyoung Woo1Ha Ryung Park2Kihwang Lee3Department of Ophthalmology, Ajou University School of MedicineDepartment of Ophthalmology, Ajou University School of MedicineDepartment of Ophthalmology, Ajou University School of MedicineDepartment of Ophthalmology, Ajou University School of MedicineAbstract We investigated the efficacy of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents in branch retinal vein occlusion (BRVO). Databases, including PubMed, EMBASE, and the Cochrane Library, were searched on November 11, 2022. Studies comparing the pro-re-nata (PRN) regimen after the first treatment (PRN group) to three consecutive monthly injection regimens followed by the PRN regimen (3 + PRN group) were investigated. The primary outcomes were the change in best-corrected visual acuity (BCVA) and the change in central retinal thickness (CRT), with the secondary outcome being the injection frequency. Among 195 reports on anti-VEGF treatment, six comparative studies were included in this meta-analysis. The two groups had no statistically significant differences in terms of BCVA or CRT. However, the total number of injections during follow-up was significantly lower in the PRN group than in the 3 + PRN group (95% CI − 2.09 to − 0.83). The as-needed injection regimen is as effective as 3-monthly loading in terms of anatomical and functional improvement for BRVO, along with a lower treatment burden for patients and physicians.https://doi.org/10.1038/s41598-023-39303-2 |
| spellingShingle | Yoo-Ri Chung Tae Kyoung Woo Ha Ryung Park Kihwang Lee Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion Scientific Reports |
| title | Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion |
| title_full | Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion |
| title_fullStr | Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion |
| title_full_unstemmed | Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion |
| title_short | Efficacy of as-needed intravitreal injection compared to 3-monthly loading of anti-vascular endothelial growth factor agents for branch retinal vein occlusion |
| title_sort | efficacy of as needed intravitreal injection compared to 3 monthly loading of anti vascular endothelial growth factor agents for branch retinal vein occlusion |
| url | https://doi.org/10.1038/s41598-023-39303-2 |
| work_keys_str_mv | AT yoorichung efficacyofasneededintravitrealinjectioncomparedto3monthlyloadingofantivascularendothelialgrowthfactoragentsforbranchretinalveinocclusion AT taekyoungwoo efficacyofasneededintravitrealinjectioncomparedto3monthlyloadingofantivascularendothelialgrowthfactoragentsforbranchretinalveinocclusion AT haryungpark efficacyofasneededintravitrealinjectioncomparedto3monthlyloadingofantivascularendothelialgrowthfactoragentsforbranchretinalveinocclusion AT kihwanglee efficacyofasneededintravitrealinjectioncomparedto3monthlyloadingofantivascularendothelialgrowthfactoragentsforbranchretinalveinocclusion |